CRISPR Therapeutics AG (CRSP) Operating Expenses (2015 - 2026)

CRISPR Therapeutics AG has disclosed Operating Expenses across 12 years of filings, most recently posting $127.4 million for Q2 2026.

• In Q2 2026, Operating Expenses fell 44.64% year-over-year to $127.4 million; the TTM figure through Jun 2026 stood at $547.7 million (down 7.25% YoY), while the FY2025 annual figure was $668.1 million, up 32.59% from the prior year.
• Operating Expenses came in at $127.4 million for Q2 2026 at CRISPR Therapeutics AG, down from $131.7 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $230.2 million in Q2 2025 to a low of $100.3 million in Q4 2024.
• Average Operating Expenses over 5 years is $150.0 million, with a median of $145.2 million recorded in 2024.
• Year-over-year, Operating Expenses soared 55.2% in 2025 and slumped 44.64% in 2026.
• Over 5 years, Operating Expenses stood at $131.5 million in 2022, then increased by 0.06% to $131.6 million in 2023, then retreated by 23.81% to $100.3 million in 2024, then soared by 55.2% to $155.6 million in 2025, then declined by 18.11% to $127.4 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $127.4 million in Q2 2026, $131.7 million in Q1 2026, and $155.6 million in Q4 2025.